Neuraxpharm Anticipates 13% Growth in 2024 and a Boost to Production in Spain

Neuraxpharm, determined to grow in the area of ​​treatments for disorders of the central nervous system (CNS). The German pharmaceutical multinational, owned since 2020 by the Permira investment fund, aims to reach 500 million euros in net sales in 2024, 13.6% more than last year’s 440 million. This increase would represent a notable boost for Spain, where a good part of its activity is concentrated.

The Spanish subsidiary of the company was established in 2016 after the purchase of Invent Farma, Qualigen, Inke and Laboratorios Lesvi by Apax Partners through the Maxwelton Investments fund. Four years later, in 2020, Permira took control of the group for 1.3 billion euros, according to figures from elEconomista.

At that time it had more than 450 employees in Spain, of the 850 it had worldwide. Currently, this figure stands at around a thousand workers in all its subsidiaries, including the commercial network, and the number of Spanish employees has not changed substantially, despite the sale of Inke to Keensight Capital.

In the last four years, with the acquisition of Permira, the pharmaceutical company has experienced significant growth after the purchase of several portfolios, among which 17 molecules representing 38 Sanofi brands in 2022 stand out. It is the largest purchase of a product portfolio in the group’s entire history, according to Neuraxpharm sources.

Neuraxpharm produces a good part of its treatments at the former Lesvi Laboratories plant in Barcelona

Among the pharmaceutical company’s operations, the incorporation in 2020 of Buccolam, a treatment for childhood epilepsy from the Japanese company Takeda, or the agreement in 2023 with TG Therapeutics to market a solution for multiple sclerosis, Briumvi, outside the United States also stands out. .

Company sources explained that these purchases are part of a growth strategy by taking advantage of the disinvestment of some large pharmaceutical companies, in the case of Sanofi or Takeda, or of associating with international companies without the capacity to market their products. all over the world, as TG Therapeutics. These divestments occur when a company understands that a certain drug is outside its core business focus .

Thanks in part to this formula, Neuraxpharm leads four markets in volume and value in Germany: epilepsy, Parkinson’s, neuroleptics and antidepressants . The company’s global growth affects Spain, since the old Lesvi Laboratories plant in Sant Joan Despí (Barcelona) centralizes a good part of the group’s production, which includes some 25 subsidiaries in Europe and Latin America.

In addition, research and development (R&D) is also carried out from Spain, something that translates into the commitment to strategic alliances such as the one signed with the Catalan company Mynorix Therapeutics to commercialize compounds . And outside the pharmacological field, for selling medical devices such as mjn-Seras, an instrument that works similar to a hearing aid with which to detect epileptic seizures before they happen.

__

(Featured image by Ibrahim Boran via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us